tiprankstipranks
Blurbs

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on IN8bio (INABResearch Report), with a price target of $12.00. The company’s shares closed last Tuesday at $2.20, close to its 52-week low of $1.90.

According to TipRanks.com, Goldstein is a 3-star analyst with an average return of 1.3% and a 34.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

IN8bio has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $10.32 and a one-year low of $1.90. Currently, IN8bio has an average volume of 13.33K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INAB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Read More on INAB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More